Skip to content

Ketamine for anxiety: all studies

Page 6 of 19: studies 51 to 60 of 187, newest first. Back to the ketamine for anxiety overview

Research

Neurological effects of ketamine: mechanisms, addiction potential, and toxicity profiles with focus on Saudi Arabia

International Journal of Community Medicine and Public Health July 17, 2025 Alanoud K. Albanna, Zayed M. Alnefaie, Atheer M. Saleh et al.

Ketamine’s rapid action and diverse physiological effects have made it an important drug in both anesthesia and mental health treatment. Clinically, it offers unique dissociative anesthetic properties, preserving stable vital signs during sedation and analgesia. Beyond its numbing effect, studies explore its influence on N-methyl-D-aspartate (NMDA) receptors and wider neurochemical systems...

Effects of cerebrolysin on behavioral changes and the tryptophan-kynurenine pathway in the prefrontal cortex of male mice in the ketamine model of schizophrenia.

Molecular Biology Reports July 16, 2025 Vida Mafikandi, Leila Hosseini, Fatemehsadat Seyedaghamiri et al.

Cerebrolysin (CBL), a peptide derived from pig brain, is recognized for its neuroprotective and anti-inflammatory properties. This research aimed to investigate the effects of CBL on anxiety- and depression-like behaviors, spatial memory, the tryptophan/kynurenine (TRP/KYN) pathway, and inflammation in the prefrontal cortex (PFC) of a mouse model for schizophrenia. Thirty-six male BALB/c mice...

DOI: 10.1007/s11033-025-10820-9 (opens in new tab) Full text (opens in new tab) Cognitive dysfunction Cerebrolysin: cerebrolysin Schizophrenia research: schizophrenia Model mimicking schizophrenia +7

Estrogen receptor alpha (ERα) partially modulates ketamine's sustained anxiolytic effects without altering its antidepressant properties in female rats.

Psychoneuroendocrinology July 1, 2025 Ece Idil, Bahar Yuksel, Zeynep Sen et al. 2 citations

Ketamine is a rapid-acting antidepressant with sexually dimorphic effects. Female animals exhibit a higher sensitivity to its antidepressant properties, which has been associated with their ovarian hormone levels. One factor contributing to this sex difference is the faster rate of ketamine metabolism observed in females, potentially regulated by estrogen receptor alpha (ERα) through modulation...

Psychedelic-Assisted Therapies for Psychosocial Symptoms in Cancer: A Systematic Review and Meta-Analysis

Current Oncology June 30, 2025 Haley D M Schuman, Chantal Savard, Raèf Mina et al. 9 citations

This systematic review and meta-analysis evaluates (1) the effectiveness of psychedelic-assisted therapy (PAT) using psilocybin and ketamine for psychosocial symptoms in adults with cancer, (2) contextualizes findings with non-randomized and exploratory studies of other psychedelics, and (3) examines the role of therapeutic frameworks in shaping outcomes. We searched PubMed, Cochrane Library,...

Heightened anxiety with distinct prefrontal substrates is differentially sensitive to the anxiolytics, citalopram and ketamine: Prefrontal substrates and anxiolytic sensitivity.

Biological Psychiatry June 25, 2025 Kevin G Mulvihill, Gemma J Cockcroft, Angela C Roberts 2 citations

Individual variability in pharmacological treatment efficacy remains a persistent obstacle to ameliorating clinical anxiety. This may originate, in part, from the different neural aetiologies underlying pathological anxiety. To provide novel insights into patient heterogeneity in anxiolytic responsiveness we compare the efficacy of distinct anxiolytic drugs, a Selective Serotonin Re-uptake...

DOI: 10.1016/j.biopsych.2025.06.013 (opens in new tab) Full text (opens in new tab) Ketamine Prefrontal cortex Orbitofrontal cortex Threat reactivity 6 +20

The Effects of Ketamine on Methamphetamine Withdrawal-Induced Anxiety and Drug-Seeking Behaviors in the Rat

bioRxiv Preprint Server June 24, 2025 Marco German Ghilotti, Ricardo Petrilli Fortuna, Kofi Osei-Abrefa Ayensu et al. preprint

Background The use of methamphetamine has continued to rise in the US. In addition to facilitating dopamine neurotransmission, methamphetamine indirectly increases glutamate release which activates N-methyl-D-aspartate receptors (NMDARs). Ketamine is a noncompetitive NMDAR antagonist. Ketamine also has actions on α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) and...

DOI: 10.1101/2025.06.24.661345 (opens in new tab) Full text (opens in new tab) Anxiety Crystal meth dependence Stimulant use disorder Methamphetamine +8

Association Between Receipt of Ketamine vs Etomidate for Emergency Tracheal Intubation and Symptoms of Posttraumatic Stress Disorder at 12 Months.

CHEST critical care June 1, 2025 Lucas C Wollenman, Austin M Tipold, Matthew W. Semler et al. 1 citation

One of 3 patients in the ICU receiving mechanical ventilation demonstrates posttraumatic stress disorder (PTSD). A single dose of ketamine has been shown to reduce PTSD symptoms in outpatients with chronic PTSD, but its long-term effect is unknown in patients who are critically ill and mechanically ventilated. Is ketamine, when used for induction of anesthesia before emergency tracheal...

Potential Antidepressive Effects of R-ketamine in Patients with Treatment Resistance Depression

Carleton undergraduate journal of science. May 16, 2025 Sumika Egner

Ketamine has a long history as an anesthetic but has recently demonstrated antidepressant effects at sub-anesthetic doses (Matveychuk et al., 2020). For individuals with treatment-resistant depression (TRD), typical antidepressants are frequently ineffective, whereas ketamine’s unique mechanisms have demonstrated promising results in reducing depressive symptoms where other treatments have...

The effect of esketamine on postoperative anxiety and depression in patients with thyroid cancer: A randomized, double-blind, placebo-controlled, parallel-group trial.

Medicine May 2, 2025 Xiaobo Bi, Junchao Dai, Jin Li 8 citations

This study aimed to investigate the effects of a single intravenous injection of esketamine during general anesthesia on postoperative anxiety and depression in patients with thyroid cancer. In this randomized, double-blind, placebo-controlled, parallel-group trial, eighty female patients with thyroid cancer were scheduled to undergo surgery under general anesthesia. The patients were randomly...

DOI: 10.1097/MD.0000000000042284 (opens in new tab) Full text (opens in new tab) Affective symptoms Postoperative complication Thyroid cancer surgery Esketamine therapy +3

Adjunctive ketamine vs. buprenorphine in co-occurring major depressive disorder and opioid use disorder: a randomized, double-blind clinical trial assessing anxiety symptom severity and craving intensity.

Trials April 17, 2025 Arash Mansoori, Amir Bazrafshan, Jamshid Ahmadi et al. 4 citations

The concomitant presence of major depressive disorder (MDD) and opioid use disorder (OUD) poses a formidable clinical challenge, warranting effective interventions that address both psychiatric and addictive components. This study sought to compare the efficacy of adjunctive ketamine and buprenorphine in mitigating anxiety symptom severity and craving intensity in individuals with co-occurring...